ER/PR Test at Lahore PCR Lab

ER/PR Test at Lahore PCR Lab

The Estrogen Receptor (ER) and Progesterone Receptor (PR) test is a highly specialized immunohistochemistry (IHC) laboratory investigation performed on breast cancer tissue samples. This test is a cornerstone of modern breast oncology, providing critical diagnostic, prognostic, and predictive information that directly influences the clinical management of breast cancer patients. At Lahore PCR Lab, located in Lahore, Pakistan, we utilize advanced automated immunohistochemistry platforms to deliver highly accurate and reproducible ER/PR testing, ensuring that patients receive the most reliable results to guide their treatment journeys.

Hormone receptors are proteins found on the surface and within the nuclei of normal breast cells. Estrogen and progesterone are hormones that naturally bind to these receptors, regulating normal breast development and function. However, in many breast cancers, the tumor cells express an abnormally high number of these receptors. When estrogen and progesterone bind to these receptors on cancer cells, they send signals that stimulate the cells to grow and divide rapidly. Identifying whether a tumor is hormone receptor-positive (HR+) or hormone receptor-negative (HR-) is essential for determining the biological subtype of the cancer and planning targeted therapeutic interventions.

The clinical importance of the ER/PR test cannot be overstated. It serves as a predictive marker, identifying patients who are highly likely to benefit from endocrine (hormone) therapy, such as selective estrogen receptor modulators (e.g., Tamoxifen) or aromatase inhibitors (e.g., Letrozole, Anastrozole, and Exemestane). Endocrine therapy works by either blocking the hormone receptors or lowering hormone levels in the body, effectively starving the cancer cells of the signals they need to grow. The ER/PR test also has significant prognostic value, as hormone receptor-positive breast cancers generally exhibit a more favorable clinical course and slower growth rate compared to hormone receptor-negative tumors.

Clinical Procedure: What to Expect

Patient Preparation

Because the ER/PR test is performed on tissue samples that have already been collected through a biopsy or surgical resection, the patient does not need to undergo any direct physical preparation, fasting, or medication adjustments on the day of the laboratory analysis. However, specific pre-analytical guidelines must be followed to ensure the integrity of the tissue sample:

• Sample Submission: If the biopsy or surgery was performed at an external hospital or clinic, patients must submit the formalin-fixed paraffin-embedded (FFPE) tissue block (often referred to as the “paraffin block”) along with the corresponding histopathology report and unstained slides to Lahore PCR Lab.
• Fixation Guidelines: To prevent false-negative results, the tissue must be fixed in 10% neutral buffered formalin as soon as possible after surgical removal. The cold ischemia time (the time from tissue removal to fixation) should ideally be less than one hour.
• Fixation Duration: The tissue sample must remain in the formalin fixative for a minimum of 6 hours and a maximum of 72 hours. Under-fixation or over-fixation can damage the receptor proteins and compromise the accuracy of the immunohistochemical staining.
• Clinical History: Patients or their representatives should provide a complete clinical history, including the primary site of the tumor, previous biopsy results, and any history of hormone therapy or chemotherapy.

During the Procedure

The ER/PR test is a multi-step laboratory procedure conducted entirely within the histopathology department of Lahore PCR Lab. The process involves the following key clinical and technical steps:

• Tissue Sectioning: A skilled histotechnologist uses a high-precision microtome to cut extremely thin sections (typically 4 to 5 micrometers thick) from the patient’s paraffin-embedded tissue block. These sections are carefully mounted onto positively charged glass slides.
• Deparaffinization and Rehydration: The slides are heated and treated with xylene to remove the paraffin wax. They are then passed through a series of graded alcohols and water to rehydrate the tissue sections.
• Antigen Retrieval: Formalin fixation causes cross-linking of proteins, which can mask the estrogen and progesterone receptor epitopes. To unmask these proteins, the slides undergo heat-induced epitope retrieval (HIER) using specialized buffer solutions in an automated retrieval system.
• Primary Antibody Incubation: Highly specific monoclonal antibodies directed against human estrogen receptor and progesterone receptor proteins are applied to the tissue sections. The slides are incubated under strictly controlled temperature and time conditions to allow the antibodies to bind specifically to the target receptors in the cell nuclei.
• Detection System: A secondary antibody conjugated with an enzyme (such as horseradish peroxidase) is applied, followed by the addition of a chromogen substrate, typically diaminobenzidine (DAB). This enzymatic reaction produces a visible brown precipitate in the nuclei of cells that express ER or PR.
• Counterstaining and Coverslipping: The slides are counterstained with hematoxylin, which colors the negative nuclei blue, providing a clear contrast with the brown positive nuclei. The slides are then dehydrated, cleared, and sealed with a coverslip.
• Pathologist Evaluation: A consultant pathologist examines the stained slides under a high-resolution microscope. The pathologist assesses the percentage of tumor cells showing nuclear staining and the intensity of the staining, calculating a semi-quantitative score (such as the Allred Score) to determine the final test result.

When is an ER/PR Test Performed?

Newly Diagnosed Invasive Breast Cancer

An ER/PR test is routinely performed on all newly diagnosed cases of invasive breast carcinoma. Whether the tumor is detected through a core needle biopsy or a surgical resection specimen, establishing the hormone receptor status is a mandatory step in the initial diagnostic workup. This information allows the multidisciplinary oncology team to classify the tumor, estimate the prognosis, and design a personalized treatment plan from the outset.

Recurrent or Metastatic Breast Cancer

In cases where breast cancer recurs locally or metastasizes to distant organs (such as the lungs, liver, bones, or brain), a biopsy of the metastatic lesion is highly recommended, and ER/PR testing must be repeated. The receptor status of metastatic tumors can differ from that of the primary tumor—a phenomenon known as receptor discordance. Re-evaluating the ER/PR status ensures that systemic therapies are adjusted to target the current biological profile of the disease.

Planning Endocrine (Hormone) Therapy

Physicians request an ER/PR test primarily to determine if a patient is a candidate for endocrine therapy. If the test reveals that the tumor is ER-positive and/or PR-positive, the patient has a high probability of responding to hormone-blocking medications. Conversely, if the tumor is negative for both receptors, endocrine therapy is highly unlikely to be effective, and the clinical team will focus on other treatment modalities, such as chemotherapy or targeted biological therapies.

Evaluating Ductal Carcinoma in Situ (DCIS)

Ductal Carcinoma in Situ (DCIS) is a non-invasive form of breast cancer. ER/PR testing is performed on DCIS tissue samples to assess whether the patient would benefit from risk-reduction endocrine therapy following breast-conserving surgery. For patients with ER-positive DCIS, taking tamoxifen or an aromatase inhibitor can significantly reduce the risk of developing a subsequent invasive breast cancer in either breast.

Prognostic Stratification and Molecular Subtyping

Oncologists use the ER/PR test, in conjunction with HER2 (Human Epidermal Growth Factor Receptor 2) and Ki-67 (a cellular proliferation marker) testing, to classify breast cancers into distinct molecular subtypes. These subtypes include Luminal A (ER/PR positive, HER2 negative, low Ki-67), Luminal B (ER/PR positive, HER2 positive or negative, high Ki-67), HER2-enriched, and Triple-Negative (ER negative, PR negative, HER2 negative). This subtyping provides critical insights into the tumor’s aggressiveness and guides the overall therapeutic strategy.

What Does an ER/PR Test Detect?

The ER/PR test is designed to detect and quantify specific molecular and cellular parameters within the tumor tissue. The analysis identifies:

• Estrogen Receptor (ER) Expression: The presence of ER proteins within the nuclei of invasive or in situ breast cancer cells.
• Progesterone Receptor (PR) Expression: The presence of PR proteins within the nuclei of the tumor cells.
• Percentage of Positive Tumor Cells: The proportion of cancer cells showing positive nuclear staining, reported on a scale from 0% to 100%.
• Nuclear Staining Intensity: The strength of the brown staining in the positive nuclei, categorized as weak, moderate, or strong.
• Allred Score: A standardized scoring system (ranging from 0 to 8) that combines the proportion of positive cells (score 0-5) and the staining intensity (score 0-3). A total score of 3 or higher is considered positive.
• Hormone Receptor-Positive Status: Defined by international guidelines (ASCO/CAP) as 1% or more of tumor cells exhibiting positive nuclear staining.
• Hormone Receptor-Negative Status: Defined as less than 1% of tumor cells exhibiting nuclear staining.
• Low-Positive ER Status: Cases with 1% to 10% of tumor cells staining positive. These are reported as low-positive, as they may have a different clinical behavior and variable response to endocrine therapy.
• Internal Positive Controls: Normal, non-malignant breast epithelial cells present within the tissue section that show positive nuclear staining, confirming the technical validity of the staining process.
• External Controls: Known positive and negative tissue samples processed alongside the patient’s slide to ensure assay reliability.
• Tumor Heterogeneity: Variations in receptor expression across different areas of the same tumor specimen.
• Tissue Fixation Quality: Assessment of whether the tissue was properly fixed, as indicated by uniform staining and preserved cellular morphology.
• Cold Ischemia Artifacts: Detection of poor or absent staining due to delayed tissue fixation.
• Necrosis and Degradation: Identification of dead or degraded tissue areas that must be excluded from the receptor evaluation.
• Invasive Tumor Component: Specific evaluation of the invasive portion of the tumor, which is critical for systemic treatment planning.
• In Situ Tumor Component: Evaluation of any non-invasive (in situ) areas, which may have a different receptor profile than the invasive component.
• Cellular Density: The concentration of tumor cells available for evaluation on the slide.
• Background Staining: The presence of non-specific background staining that could interfere with the interpretation of nuclear positivity.
• Edge Artifacts: Artificial staining patterns at the edges of the tissue section that must be ignored during scoring.
• Decalcification Effects: Assessment of whether decalcification (in bone metastasis samples) has compromised the antigenicity of the receptors.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we recognize that receiving a breast cancer diagnosis and waiting for pathology results can be an anxious time for patients and their families. Because immunohistochemistry (IHC) is a highly complex, multi-step process that requires precise technical execution and expert microscopic analysis, the turnaround time for the ER/PR test is typically 3 to 5 working days from the time the tissue sample or paraffin block is received at our main laboratory.

We are committed to providing seamless and convenient access to diagnostic reports. Once the consultant pathologist finalizes and signs off on the ER/PR report, patients receive an automated SMS notification on their registered mobile number. The report can be downloaded immediately in PDF format from the official Lahore PCR Lab online portal. Physical copies of the report can also be collected from our main facility in Lahore or any of our designated collection centers. Our reports are designed to be comprehensive, featuring detailed descriptions of the staining percentage, intensity, Allred scores, and high-quality microscopic findings.

ER/PR Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Estrogen Receptor (ER) Status	Negative (No nuclear staining in malignant cells; normal breast tissue has regulated expression)	Positive (1% to 100% of tumor cell nuclei show positive brown staining)
Progesterone Receptor (PR) Status	Negative (No nuclear staining in malignant cells; normal breast tissue has regulated expression)	Positive (1% to 100% of tumor cell nuclei show positive brown staining)
Allred Score (ER & PR)	Score of 0 or 2 (Indicates negative receptor status)	Score of 3 to 8 (Indicates positive receptor status, with higher scores indicating stronger expression)
Staining Intensity	No staining (Intensity score 0)	Weak (Score 1), Moderate (Score 2), or Strong (Score 3) nuclear staining
Proportion of Positive Cells	0% of tumor cells stained	1% to 100% of tumor cells stained (higher percentages correlate with better response to hormone therapy)
Internal Control (Normal Epithelium)	Positive nuclear staining in normal adjacent breast ducts	Negative staining in normal adjacent ducts (indicates technical failure or fixation artifact)
Molecular Subtype Classification	Not applicable (Non-malignant tissue)	Luminal A, Luminal B, HER2-enriched, or Triple-Negative breast cancer profiles
Tissue Fixation Quality	Well-preserved cellular morphology with uniform staining	Patchy staining, edge artifacts, or background staining due to poor fixation or tissue degradation

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for ER/PR?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant histopathologists with extensive experience in oncopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient well-being, ensuring that every sample is handled with the utmost care, precision, and clinical urgency.
• Quality Diagnostic Services: Lahore PCR Lab adheres to international standards of quality control and quality assurance in immunohistochemical staining.
• Professional Reporting: Our reports are detailed, comprehensive, and structured according to international guidelines (ASCO/CAP), providing clear Allred scores and staining percentages.
• Modern Diagnostic Approach: We utilize advanced, automated IHC platforms that minimize manual errors and ensure highly reproducible staining results.
• Comfortable Environment: Our main laboratory and collection centers offer a professional, clean, and welcoming environment for patients and their families.
• Convenient Location: Centrally located in Lahore, our main facility and extensive network of collection centers make sample submission easy and accessible.
• Commitment to Accurate Diagnosis: We are dedicated to providing evidence-based, clinically precise diagnostic outcomes that oncologists can trust to make critical treatment decisions.